|
1
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Casimiro MC, Crosariol M, Loro E, Li Z and
Pestell RG: Cyclins and cell cycle control in cancer and disease.
Genes Cancer. 3:649–657. 2012. View Article : Google Scholar
|
|
3
|
Dhavan R and Tsai LH: A decade of CDK5.
Nat Rev Mol Cell Biol. 2:749–759. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shupp A, Casimiro MC and Pestell RG:
Biological functions of CDK5 and potential CDK5 targeted clinical
treatments. Oncotarget. 8:17373–17382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X, Zhong T, Dang Y, Li Z, Li P and
Chen G: Aberrant expression of CDK5 infers poor outcomes for
nasopharyngeal carcinoma patients. Int J Clin Exp Pathol.
8:8066–8074. 2015.PubMed/NCBI
|
|
6
|
Zhuang K, Zhang J, Xiong M, Wang X, Luo X,
Han L, Meng Y, Zhang Y, Liao W and Liu S: CDK5 functions as a tumor
promoter in human colorectal cancer via modulating the ERK5-AP-1
axis. Cell Death Dis. 7:e24152016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang R, Lin P, Yang H, He Y, Dang YW,
Feng ZB and Chen G: Clinical role and biological function of CDK5
in hepatocellular carcinoma: A study based on immunohistochemistry,
RNA-seq and in vitro investigation. Oncotarget. 8:108333–108354.
2017.
|
|
8
|
Pan DH, Zhu ML, Lin XM, Lin XG, He RQ,
Ling YX, Su ST, Wickramaarachchi MM, Dang YW, Wei KL and Chen G:
Evaluation and clinical significance of cyclin-dependent kinase5
expression in cervical lesions: A clinical research study in
Guangxi, China. Eur J Med Res. 21:282016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei K, Ye Z, Li Z, Dang Y, Chen X, Huang
N, Bao C, Gan T, Yang L and Chen G: An immunohistochemical study of
cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung
cancer (NSCLC) and small cell lung cancer (SCLC): A possible
prognostic biomarker. World J Surg Oncol. 14:342016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun SS, Zhou X, Huang YY, Kong LP, Mei M,
Guo WY, Zhao MH, Ren Y, Shen Q and Zhang L: Targeting STAT3/miR-21
axis inhibits epithelial-mesenchymal transition via regulating CDK5
in head and neck squamous cell carcinoma. Mol Cancer. 14:2132015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang S, Lu Z, Mao W, Ahmed AA, Yang H,
Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda
R, et al: CDK5 regulates paclitaxel sensitivity in ovarian cancer
cells by modulating AKT activation, p21Cip1- and p27Kip1-Mediated
G1 cell cycle arrest and apoptosis. PLoS One. 10:e01318332015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li R, Liu GZ, Luo SY, Chen R and Zhang JX:
Cyclin I promotes cisplatin resistance via Cdk5 activation in
cervical cancer. Eur Rev Med Pharmacol Sci. 19:4533–4541.
2015.PubMed/NCBI
|
|
13
|
Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De
Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL and
Vollmar AM: Targeting cyclin dependent kinase 5 in hepatocellular
carcinoma-A novel therapeutic approach. J Hepatol. 6:102–113. 2015.
View Article : Google Scholar
|
|
14
|
Merk H, Zhang S, Lehr T, Müller C, Ulrich
M, Bibb JA, Adams RH, Bracher F, Zahler S, Vollmar AM and Liebl J:
Inhibition of endothelial Cdk5 reduces tumor growth by promoting
non-productive angiogenesis. Oncotarget. 7:6088–6104. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ri M: Endoplasmic-reticulum stress
pathway-associated mechanisms of action of proteasome inhibitors in
multiple myeloma. Int J Hematol. 104:273–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levacque Z, Rosales JL and Lee KY: Level
of cdk5 expression predicts the survival of relapsed multiple
myeloma patients. Cell Cycle. 11:4093–4095. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu YX, Tiedemann R, Shi CX, Yin H,
Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S
and Stewart AK: RNAi screen of the druggable genome identifies
modulators of proteasome inhibitor sensitivity in myeloma including
CDK5. Blood. 117:3847–3857. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alagpulinsa DA, Ayyadevara S, Yaccoby S
and Shmookler Reis RJ: A cyclin-dependent kinase inhibitor,
dinaciclib, impairs homologous recombination and sensitizes
multiple myeloma cells to PARP inhibition. Mol Cancer Ther.
15:241–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nguyen TK and Grant S: Dinaciclib
(SCH727965) inhibits the unfolded protein response through a CDK1-
and 5-dependent mechanism. Mol Cancer Ther. 13:662–674. 2014.
View Article : Google Scholar
|
|
20
|
Kumar SK, LaPlant B, Chng WJ, Zonder J,
Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK, et
al: Dinaciclib, a novel CDK inhibitor, demonstrates encouraging
single-agent activity in patients with relapsed multiple myeloma.
Blood. 125:443–448. 2015. View Article : Google Scholar :
|
|
21
|
Tang H, Shu M, Dai B, Xu L, Dong B, Gao G
and Chen X: DNA damage response-initiated cytokine secretion in
bone marrow stromal cells promotes chemoresistance of myeloma
cells. Leuk Lymphoma. 59:2220–2226. 2018. View Article : Google Scholar
|
|
22
|
Roy P, Sarkar UA and Basak S: The NF-κB
activating pathways in multiple myeloma. Biomedicines. 6:pii: E59.
2018. View Article : Google Scholar
|
|
23
|
Hideshima T, Chauhan D, Richardson P,
Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A,
Palombella V, et al: NF-kappa B as a therapeutic target in multiple
myeloma. J Biol Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hoffmann A, Natoli G and Ghosh G:
Transcriptional regulation via the NF-kappaB signaling module.
Oncogene. 25:6706–6716. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pozo K, Castro-Rivera E, Tan C, Plattner
F, Schwach G, Siegl V, Meyer D, Guo A, Gundara J, Mettlach G, et
al: The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell.
24:499–511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burkhart DL and Sage J: Cellular
mechanisms of tumour suppression by the retinoblastoma gene. Nat
Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang H, Xu L, Liang X and Gao G: Low dose
dinaciclib enhances doxorubicin-induced senescence in myeloma
RPMI8226 cells by transformation of the p21 and p16 pathways. Oncol
Lett. 16:6608–6614. 2018.PubMed/NCBI
|
|
29
|
Ballabio E, Armesto M, Breeze CE,
Manterola L, Arestin M, Tramonti D, Hatton CS and Lawrie CH:
Bortezomib action in multiple myeloma: MicroRNA-mediated synergy
(and miR-27a/CDK5 driven sensitivity)? Blood Cancer J. 2:e832012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar
|
